Safety and efficacy of tofacitinib for up to 9.5 years in the treatment of rheumatoid arthritis: final results of a global, open-label, long-term extension study

BACKGROUND: Final data are presented for the ORAL Sequel long-term extension (LTE) study evaluating the safety and efficacy of tofacitinib 5 mg and 10 mg twice daily (BID) for up to 9.5 years in patients with rheumatoid arthritis (RA). METHODS: Eligible patients had previously completed a phase 1, 2...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Arthritis Res Ther
Main Authors: Wollenhaupt, Jürgen, Lee, Eun-Bong, Curtis, Jeffrey R., Silverfield, Joel, Terry, Ketti, Soma, Koshika, Mojcik, Chris, DeMasi, Ryan, Strengholt, Sander, Kwok, Kenneth, Lazariciu, Irina, Wang, Lisy, Cohen, Stanley
Formato: Artigo
Idioma:Inglês
Publicado em: BioMed Central 2019
Assuntos:
Research Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6451219/
https://ncbi.nlm.nih.gov/pubmed/30953540
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13075-019-1866-2
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados